Table 4 Delays in Xpert MTB/Rif® testing in patients who underwent this test after TB treatment initiation in Bago Region, Myanmar, October 2016–March 2017.
Characteristic | Total (%) | Median days for GXP testing after TB treatment initiation (IQR) |
|---|---|---|
Total | 381 | 6 (1–10) |
Age | ||
<15 yrs | 1 (0.3) | 1 (1–1) |
15–44 yrs | 167 (44) | 6 (3–14) |
45–64 yrs | 148 (39) | 6 (3–13) |
>/=65 yrs | 65 (17) | 7 (3–14) |
Sex | ||
Female | 122 (32%) | 6 (3–12) |
Male | 259 (68%) | 7 (2–13) |
Health Facility* | ||
Township with GXP machine | 118 (31%) | 3 (1–7)* |
Township without GXP Machine | 263 (69%) | 8 (4–15)* |
TB site | ||
Pulmonary TB | 372 (98%) | 6 (3–13) |
Extra-pulmonary TB | 3 (0.8%) | 18 (12–27) |
Not recorded | 6 (2%) | Â |
Sputum smear status (pulmonary TB cases) | 372 | Â |
Smear positive | 246 (66%) | 6 (2–12) |
Smear negative | 125 (34%) | 7 (3–15) |
Not recorded | 1 (0%) | Â |
Time of GXP Testing | 848 | Â |
Before Treatment | 390 (46%) | — |
On Treatment Date | 77 (9%) | — |
After Treatment | 381 (45%) | — |
